Opendata, web and dolomites

MBLIs SIGNED

New Approaches to Metallo-β-Lactamase Inhibitors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MBLIs project word cloud

Explore the words cloud of the MBLIs project. It provides you a very rough idea of what is the project "MBLIs" about.

interdisciplinary    variations    resistance    pioneer    metallo    denaturing    combination    organic    synthesis    lactamases    representing    occurrence    pbps    mbls    human    infections    mblis    directed    breadth    resistant    situation    catalyse    little    sbl    serine    relevance    declining    mbl    blas    phosphinic    almost    screening    31p    panel    dcls    clear    compounds    mechanisms    enzymes    structures    alarming    desired    bacterial    health    nmr    acids    binding    inhibition    gt    molecules    hydrolysis    representative    small    mechanistically    structurally    patients    biology    unlike    biological    antibiotics    bla    inhibitors    public    society    60    antibiotic    utility    medicinal    esi    least    lactam    beta    obtain    unrelated    dcc    ring    generation    threat    caused    reporter    phosphonates    spectrum    healthcare    serious    chemistry    protein    mbli    modified    broad    active    billion    mechanism    ms    selectivity    clinically    pathogens    contain    die    inactive    penicillin    clinical    therapies    structural    inhibited    25    efficacy    inspire    critical    equilibrated    rendering    spends    global    sites    coupled   

Project "MBLIs" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 

Organization address
address: WELLINGTON SQUARE UNIVERSITY OFFICES
city: OXFORD
postcode: OX1 2JD
website: www.ox.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://schofield.chem.ox.ac.uk/mariosmarkoulides.aspx
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) coordinator 183˙454.00

Map

 Project objective

The increasing problem of antibiotic resistance is a major global public health concern. In the EU 25,000 patients die each year due to infections caused by multi-resistant bacterial pathogens, and the EU spends at least 1.5 billion euro per year on healthcare costs. The β-lactam antibiotics are the most important antibiotics representing >60% of small molecules in clinical use. BLAs contain a β-lactam ring which is critical for penicillin-binding protein inhibition. However, BLA efficacy is declining due to resistance mechanisms including the widespread occurrence of β-lactamases, which catalyse β-lactam hydrolysis. Metallo-β-lactamases, long-considered as of little clinical relevance, now present a serious global threat to almost all BLAs, rendering the development of approaches to MBL inhibitors important. Unlike the serine β-lactamases, the MBLs are structurally and mechanistically unrelated to PBPs, and are not inhibited by current mechanism-based SBL inhibitors. Due to variations in MBL structures, a major challenge in MBL inhibition is the development of compounds with the breadth of selectivity necessary for clinical utility. Society is now in an alarming situation and there is a clear need for the development of an MBLI:β-lactam-based combination therapies. The aim of my proposed work is to pioneer, enable and inspire the generation of broad-spectrum MBLIs active against a panel of clinically representative MBLs, but inactive against human enzymes with related active sites. To obtain the desired objective, novel approaches are proposed and include the use of phosphonates and phosphinic acids for: (a) MBL-directed DCC coupled to analysis by non-denaturing ESI-MS and 31P-NMR, (b) 31P-NMR reporter screening method, (c) pre-equilibrated DCLs for MBL-directed DCC, and (d) the synthesis of modified inhibitors. The study will be interdisciplinary and encompass organic synthesis, biological MS/NMR, structural biology, and medicinal chemistry.

 Publications

year authors and title journal last update
List of publications.
2016 David Yuxin Wang, Martine I Abboud, Marios S Markoulides, Jürgen Brem, Christopher J Schofield
The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam
published pages: 1063-1084, ISSN: 1756-8919, DOI: 10.4155/fmc-2016-0078
Future Medicinal Chemistry 8/10 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MBLIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MBLIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NSTree (2020)

Understanding substrate delivery for cell wall biosynthesis in plants

Read More  

PHOTOCARBOX (2020)

Increasing the scope of CO2-utilising photoreactions: asymmetric photosynthesis of amino acids

Read More  

ReproMech (2019)

The Molecular Mechanisms of Cell Fate Reprogramming in Vertebrate Eggs

Read More